


## Deslanoside

## Chemical Properties

CAS No. :	17598-65-1
Formula:	C <sub>47</sub> H <sub>74</sub> O <sub>19</sub>
Molecular Weight:	943.08
Storage:	Keep away from direct sunlight, Keep away from moisture Powder: -20°C for 3 years   In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



## Biological Description

Description	Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias associated with reentry mechanisms. It inhibits the Na-K-ATPase membrane pump, increasing intracellular sodium and calcium concentrations.
Targets(IC50)	ATPase, Drug Metabolite
In vitro	Deslanoside increases forearm blood flow and cardiac index and decreased heart rate concomitant with a marked decrease in skeletal muscle sympathetic nerve activity [1]. Deslanoside is a metabolite of Lanatoside C [3].

## Solubility Information

Solubility	DMSO: 95 mg/mL (100.73 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (3.5 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	1.0604 mL	5.3018 mL	10.6036 mL
5 mM	0.2121 mL	1.0604 mL	2.1207 mL
10 mM	0.106 mL	0.5302 mL	1.0604 mL
50 mM	0.0212 mL	0.106 mL	0.2121 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Hauptman PJ, et al. Digitalis. *Circulation*. 1999 Mar 9;99(9):1265-70.

Wang L, et al. Ontology-based systematical representation and drug class effect analysis of package insert-reported adverse events associated with cardiovascular drugs used in China. *Sci Rep*. 2017 Oct 23;7(1):13819.

Klys M, et al. Determination of deslanoside in antemortem and postmortem specimens. Unusual case report. *Forensic Sci Int*. 1990 Apr;45(3):231-8.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481